



**CORPORATE INQUIRIES TO:**

Karen Miller  
[Karen.Miller@sial.com](mailto:Karen.Miller@sial.com)

**MEDIA INQUIRIES TO:**

Mitzi Rettinger, (512) 310-5105  
[Mitzi.Rettinger@cerilliant.com](mailto:Mitzi.Rettinger@cerilliant.com)

## Cerilliant Introduces Certified Spiking Solutions<sup>®</sup> of Tryptamines

**ST. LOUIS – February 24, 2015** – Sigma-Aldrich Corporation (NASDAQ: SIAL) is pleased to announce that the Cerilliant<sup>®</sup> brand within its Applied Diagnostics and Testing business is introducing eight new Certified Spiking Solutions<sup>®</sup> of tryptamines for use in quantitative mass spec-based testing applications such as forensic analysis, clinical toxicology, urine drug testing, or pharmaceutical research. This product introduction includes solution CRMs for five synthetic tryptamines 5-MeO-AMT, 5-MeO-DALT, 5-MeO-MiPT, 5-MeO-DMT, and 5-MeO-DiPT in addition to three naturally occurring tryptamines N, N-dimethyltryptamine; psilocybin; and its stable-labeled internal standard.

These tryptamine reference standards represent the latest additions to Cerilliant's offering of hallucinogen certified reference materials (CRMs), which include dissociatives, LSD and its derivatives, NBOMe analogs, and other hallucinogenic novel psychoactive substances. Since these chemicals are generally controlled, Cerilliant supplies its Certified Spiking Solutions<sup>®</sup> of tryptamines in a USDEA and Health Canada with Test Kit Numbers (TK#s)-exempt solution format.

Natural and synthetic tryptamines are used recreationally for their hallucinogenic and stimulant properties. In recent years, tryptamines have experienced a resurgence of abuse due to their ease of availability on clandestine and legal websites combined with a growing trend among drug users to vaporize tryptamines using e-cigarette devices.<sup>1,2</sup> Tryptamines have also emerged as a potential tool in identifying targets for new antipsychotic drugs and as a potential therapeutic for managing psychiatric illnesses such as depression and bipolar disorder.<sup>3,4</sup>

Cerilliant's reference standards are manufactured and certified to the highest industry standards including ISO Guide 34, ISO/IEC 17025, and ISO 13485 and are compliant with ISO 15194.

**About Cerilliant:** Cerilliant Corporation, located in Round Rock, Texas, is a global leader in providing certified reference standards for critical applications. The company has been providing Certified Reference Materials for over 30 years. Cerilliant offers more than 3,000 catalog products and a full range of custom products and services that address the stringent and complex requirements of the pharmaceutical, clinical diagnostic, clinical/forensic toxicology, and natural products industries. Cerilliant sustains a modern, robust quality system, which incorporates cGMP, GLP, and ISO requirements. The company is accredited to ISO Guide 34 and ISO/IEC 17025, is certified to ISO 13485 and ISO 9001:2008, and is compliant with ISO 17511 and ISO 15194. Cerilliant Corporation is a subsidiary of Sigma-Aldrich. For more information about Cerilliant, please visit [www.cerilliant.com](http://www.cerilliant.com).

**About Sigma-Aldrich:** Sigma-Aldrich, a leading Life Science and Technology company focused on enhancing human health and safety, manufactures and distributes 250,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units - Research, Applied and SAFC Commercial - Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 37 countries, has approximately 9,300 employees worldwide and had sales of \$2.79 billion in 2014.

For more information about Sigma-Aldrich, please visit its website at [www.sigma-aldrich.com](http://www.sigma-aldrich.com).

Sigma-Aldrich, Cerilliant, Snap-N-Spike, and Snap-N-Shoot are registered trademarks of Sigma-Aldrich Co. LLC or an affiliated company.

1. <http://informahealthcare.com/doi/abs/10.3109/15563650.2014.885983>
2. <http://www.mirror.co.uk/news/technology-science/technology/digital-druggies-turn-electronic-cigarettes-4928383>
3. <http://ijnp.oxfordjournals.org/content/17/8/1269>
4. <http://www.sciencedirect.com/science/article/pii/S0924977X13003519>